Biological therapy in cardiology - New studies with antibodies directed against PCSK9

Abstract

The safety and efficacy of PCSK9 inhibitors being tested in an extensive research program. This new therapeutic option offers hope for difficult to treat patients with familial hypercholesterolemia, or intolerant of statins.

Keywords

• cardiovascular risk
• LDL-cholesterol
• lipid lowering drugs
• PCSK9
• monoclonal antibody